{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"submitter":["Leonard L"],"funding":["NCI NIH HHS","MD Anderson Cancer Center"],"pubmed_abstract":["<h4>Background</h4>In patients with hormone receptor-positive (HR<sup>+</sup>), HER2-negative breast cancer, there is a lack of data available to define optimal axillary management strategies after neoadjuvant endocrine therapy (NET).<h4>Patients and methods</h4>We performed a retrospective review of patients with clinical stage I-III, HR<sup>+</sup> breast cancer who received > 90 days of NET at a single comprehensive cancer center between 2004 and 2024.<h4>Results</h4>A total of 230 patients were included; 120 (52.2%) were clinically node-negative (cN0), while 110 (47.8%) were clinically node-positive (cN+). In the cN+ group, 7.3% (8/110) had a nodal pathologic complete response (pCR). In total, 76.4% (84/110) in the cN+ group underwent axillary lymph node dissection (ALND) as the initia"],"journal":["Annals of surgical oncology"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12866965"],"repository":["biostudies-literature"],"pubmed_title":["Axillary Management after Neoadjuvant Endocrine Therapy (NET)."],"pmcid":["PMC12866965"],"funding_grant_id":["P30 CA016672","CA16672"],"pubmed_authors":["Caudle A","Hwang RF","Wingate E","Valero V","Litton J","Hunt KK","Yi M","Singh P","Leonard L","Ibrahim N","Bedrosian I"],"additional_accession":[]},"is_claimable":false,"name":"Axillary Management after Neoadjuvant Endocrine Therapy (NET).","description":"<h4>Background</h4>In patients with hormone receptor-positive (HR<sup>+</sup>), HER2-negative breast cancer, there is a lack of data available to define optimal axillary management strategies after neoadjuvant endocrine therapy (NET).<h4>Patients and methods</h4>We performed a retrospective review of patients with clinical stage I-III, HR<sup>+</sup> breast cancer who received > 90 days of NET at a single comprehensive cancer center between 2004 and 2024.<h4>Results</h4>A total of 230 patients were included; 120 (52.2%) were clinically node-negative (cN0), while 110 (47.8%) were clinically node-positive (cN+). In the cN+ group, 7.3% (8/110) had a nodal pathologic complete response (pCR). In total, 76.4% (84/110) in the cN+ group underwent axillary lymph node dissection (ALND) as the initia","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Dec","modification":"2026-07-14T21:03:55.804Z","creation":"2026-06-25T03:08:20.565Z"},"accession":"S-EPMC12866965","cross_references":{"pubmed":["41455847"],"doi":["10.1245/s10434-025-18916-z"]}}